[Utility of the AGREE tool for the development and evaluation of clinical protocols: From theory to clinical practice]. / Utilidad del instrumento AGREE para la elaboración y la evaluación de protocolos clínicos: de la teoría a la práctica clínica.

INTRODUCTION AND OBJECTIVE: Clinical protocols are tools for the delivery of optimal and quality healthcare. However, there are often shortcomings in the quality of their design that invalidate their implementation. The aim of this study is to describe a systematic evaluation of clinical protocols, to analyse their quality in order to enable their implementation. MATERIALS AND METHODS: Descriptive study that included the clinical protocols assessed by the Committee of Reviewers of Clinical Practice Recommendations and Health Technologies of a tertiary hospital during 11years of its existence between 2013 and 2023. The AGREE instrument was used to assess the quality of the protocols received, calculating standardised scores by item and domain, and categorising them into: a)excellent (90-100%), b)good (70-89%), c)improvable (50-69%), d)very improvable (30-49%), e)deficient (10-29%), and f)very deficient: 0-9%. RESULTS: Of the 59 documents received by the Commission, 32 were subsidised for AGREE evaluation. The highest scoring domain was «Scope and objective¼, with excellent scores for 29 protocols; the remaining domains had scores ranging from 58.5%-100% for «Rigour in elaboration¼ and 0-100% for «Independence¼. By items, scores ranged from 85.7-100% for «Target users of the protocol are clearly defined¼ to 0-100% for the items «Potential costs of implementing recommendations¼ and «Conflict of interest¼. Of the 32 protocols, 9 were highly recommended, 22 were recommended with modifications/conditions and one was not recommended. CONCLUSIONS: The AGREE tool makes it possible to systematize both the drafting of clinical protocols by the authors and their evaluation by the Clinical Practice Recommendations and Health Technologies Review Committee. This makes it possible to have applicable and quality protocols in our hospital, which results in an improvement in the quality of healthcare.

Valor pronóstico de una reevaluación precoz de la fracción de eyección reducida en insuficiencia cardíaca aguda / Prognostic value of early reassessment of reduced ejection fraction in acute heart failure

Background and objectives An improvement in left ventricular ejection fraction (LVEF) in patients with heart failure (HF) is associated with a better prognosis. Identifying these subjects early after an episode of decompensation, the necessary threshold of LVEF improvement, and its predictive factors are of great interest. Patients and methods One hundred and ten patients hospitalized for HF were prospectively reassessed at an early outpatient visit (mean of 38 days). Results and conclusions In subjects with depressed LVEF (<50%), 50.7% presented an improvement in LVEF≥5% between the acute episode and the outpatient visit. This improvement in depressed LVEF was found to be useful for identifying patients with a good prognosis (readmission due to HF+cardiovascular mortality, p=0.022) but not in patients with preserved LVEF (≥50%). Patients with improved LVEF were significantly younger and had new-onset HF, a better global longitudinal strain (GLS), and better renal function. A multivariate logistic regression model found GLS, new-onset HF, and a lower LV mass index as predictors of LVEF improvement ≥5% (AUC 0.85) (AU)

Antecedentes y objetivo La mejoría en la fracción de eyección de ventrículo izquierdo (FEVI) en insuficiencia cardíaca (IC) se relaciona con un mejor pronóstico. Identificar estos sujetos precozmente tras una descompensación, el umbral necesario de mejoría de FEVI y sus factores predictores resultan de gran interés. Pacientes y métodos Se reevaluaron prospectivamente 110 pacientes hospitalizados por IC en una visita ambulatoria precoz (media 38 días). Resultados y conclusiones En sujetos con FEVI deprimida (<50%) un 50,7% presentaron una mejoría de FEVI≥5% entre el episodio agudo y la visita ambulatoria. Esta mejoría en FEVI deprimida resultó ser útil para identificar pacientes con buen pronóstico (reingreso por IC+mortalidad cardiovascular, p=0,022), pero no en FEVI preservada (≥50%). Los pacientes con FEVI mejorada presentaban significativamente menor edad, debut de IC, mejor strain longitudinal global (SLG) y función renal. Un modelo de regresión logística multivariante seleccionó al SLG, debut de IC y un menor tamaño ventricular izquierdo como predictores de mejoría de FEVI≥5% (AUC 0,85) (AU)

Prognostic value of early reassessment of reduced ejection fraction in acute heart failure.

BACKGROUND AND OBJECTIVES: An improvement in left ventricular ejection fraction (LVEF) in patients with heart failure (HF) is associated with a better prognosis. Identifying these subjects early after an episode of decompensation, the necessary threshold of LVEF improvement, and its predictive factors are of great interest. PATIENTS AND METHODS: One hundred and ten patients hospitalized for HF were prospectively reassessed at an early outpatient visit (mean of 38 days). RESULTS AND CONCLUSIONS: In subjects with depressed LVEF (<50%), 50.7% presented an improvement in LVEF≥5% between the acute episode and the outpatient visit. This improvement in depressed LVEF was found to be useful for identifying patients with a good prognosis (readmission due to HF+cardiovascular mortality, p=0.022) but not in patients with preserved LVEF (≥50%). Patients with improved LVEF were significantly younger and had new-onset HF, a better global longitudinal strain (GLS), and better renal function. A multivariate logistic regression model found GLS, new-onset HF, and a lower LV mass index as predictors of LVEF improvement ≥5% (AUC 0.85).

Ausencia de implicación de la cistatina C en el remodelado ventricular y la insuficiencia cardiaca / Absence of cystatin C involvement in ventricular remodelling and heart failure

La cistatina C (CisC) es una proteasa codificada por genes de mantenimiento («housekeeping genes»). Aunque su valor pronóstico en la insuficiencia cardiaca (IC) es bien conocido, se debate si es debido a su mayor precisión en la estimación del filtrado glomerular, o a su implicación en el remodelado ventricular patológico. El propósito de este estudio fue comprobar si la expresión de CisC se modificaba en el miocardio de fetos de diferentes edades y en el de adultos con diversas enfermedades cardiovasculares, así como analizar la correlación entre sus concentraciones séricas y la estructura y morfología cardiaca en un grupo de pacientes con IC. Pacientes y métodos. Se analizaron las correlaciones (test de Pearson y Spearman) entre la CisC sérica y los parámetros ecocardiográficos de 351 pacientes con IC. También se realizó una tinción inmunohistoquímica para CisC, metaloproteinasa 9 (MMP-9) y desmina en 9 muestras de tejido cardiaco procedentes de las autopsias de 4 fetos con diferente edad gestacional y 5 adultos sanos o con enfermedad cardiovascular. Resultados. En pacientes con IC no se encontró correlación entre las concentraciones de CisC y los parámetros cardiacos medidos por ecocardiografía 2D. La inmunohistoquímica mostró una débil tinción de fondo para CisC en todas las muestras, independientemente de la edad y la presencia o no de enfermedades cardiovasculares. Conclusiones. Nuestros resultados sugieren que la CisC no tiene un papel significativo en el remodelado patológico del ventrículo izquierdo en la IC (AU)

Cystatin C (CysC) is a protease encoded by housekeeping genes. Although its prognostic value in heart failure (HF) is well known, it is debatable whether this value is due to the greater accuracy of CysC in calculating the glomerular filtration rate or to its involvement in pathological ventricular remodelling. The aim of this study was to determine whether CysC expression changes in the myocardium of foetuses of different ages and in the myocardium of adults with various cardiovascular diseases, as well as to analyse the correlation between its serum concentrations and cardiac structure and morphology in a patient group with HF. Patients and methods. We analysed the correlations (Pearson's r and Spearman's test) between the serum CysC levels and echocardiographic parameters of 351 patients with HF. We also performed immunohistochemical staining for CysC, metalloproteinase-9 (MMP-9) and desmin in 9 cardiac tissue samples from autopsies of 4 foetuses of different gestational ages and 5 healthy adults or adults with cardiovascular disease. Results. For the patients with HF, there was no correlation between the CysC concentrations and the cardiac parameters measured by 2D echocardiography. The immunohistochemistry showed a weak background staining for CysC in all samples, regardless of age and the presence or absence of cardiovascular diseases. Conclusions. Our results suggest that CysC does not have a significant role in the pathological remodelling of the left ventricle in HF (AU)

Absence of cystatin C involvement in ventricular remodelling and heart failure.

UNLABELLED: Cystatin C (CysC) is a protease encoded by housekeeping genes. Although its prognostic value in heart failure (HF) is well known, it is debatable whether this value is due to the greater accuracy of CysC in calculating the glomerular filtration rate or to its involvement in pathological ventricular remodelling. The aim of this study was to determine whether CysC expression changes in the myocardium of foetuses of different ages and in the myocardium of adults with various cardiovascular diseases, as well as to analyse the correlation between its serum concentrations and cardiac structure and morphology in a patient group with HF. PATIENTS AND METHODS: We analysed the correlations (Pearson's r and Spearman's test) between the serum CysC levels and echocardiographic parameters of 351 patients with HF. We also performed immunohistochemical staining for CysC, metalloproteinase-9 (MMP-9) and desmin in 9 cardiac tissue samples from autopsies of 4 foetuses of different gestational ages and 5 healthy adults or adults with cardiovascular disease. RESULTS: For the patients with HF, there was no correlation between the CysC concentrations and the cardiac parameters measured by 2D echocardiography. The immunohistochemistry showed a weak background staining for CysC in all samples, regardless of age and the presence or absence of cardiovascular diseases. CONCLUSIONS: Our results suggest that CysC does not have a significant role in the pathological remodelling of the left ventricle in HF.

Flúter auricular en un recién nacido pretérmino / Atrial flutter in preterm newborn

Se comunica un caso de flúter auricular en un recién nacido pretérmino con insuficiencia cardiaca, mala respuesta farmacológica y recuperación del ritmo normal tras una cardioversión eléctrica (AU)

We describe an atrial flutter in preterm newborn with heart failure, resistant to pharmacological treatment and recovery of the normal heart rhythm after electrical cardioversion (AU)

Disfunción valvular protésica con síntomas atípicos. ¿Endocarditis o trombosis? / Prosthetic valve dysfunction with atypical symptoms. Endocarditis or trombosis?

No disponible

Trombo intraventricular y angioma cavernoso en cerebelo: disyuntiva de terapéutica hipocoagulante / Left ventricular thrombus and cavernous angioma of the cerebellum: controversy of the hypocoagulant therapy

No disponible